Risk-reducing mastectomy in BRCA1/2 mutation carriers: Factors influencing uptake and timing



      Strategies in case of high risk of breast cancer in BRCA1/2 mutation carriers are either intensive breast cancer screening or risk-reducing mastectomy (RRM). Both options have a high physical and psychosexual impact. The aim of this study is to investigate who chooses when to undergo RRM.


      BRCA1/2 mutation carriers have been prospectively registered at the family cancer clinic between 1994 and 2011. Analyses were performed to assess the relation between characteristics of the BRCA1/2 mutation carriers and an earlier decision for RRM.


      A cumulative percentage of 35.6% of all women chose to undergo RRM within the first five years after disclosure of DNA test results. Women needed less time to choose for RRM measured from the first visit, if they were younger than 50 years of age (hazard ratio (HR) = 2.67, 95% confidence interval (CI) = 1.30–5.48) or had a mother who had had breast cancer (HR = 1.51 95% CI = 1.04–2.18). Also, women needed less time to choose for RRM in case of a previous breast cancer (HR = 2.25, 95% CI = 1.55–3.27). After a previous unilateral therapeutic mastectomy as a treatment for breast cancer, women needed less time to choose for RRM of the contralateral breast (HR = 2.69, 95% CI = 1.29–5.62) compared to women who had had breast-conserving therapy.


      BRCA1/2 mutation carriers aged under 50, having a mother with breast cancer, who had previous unilateral breast cancer and previous unilateral therapeutic mastectomy chose more often and earlier for RRM.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
        Am J Hum Genet. 2003; 72: 1117-1130
        • Chen S.
        • Parmigiani G.
        Meta-analysis of BRCA1 and BRCA2 penetrance.
        J Clin Oncol. 2007; 25: 1329-1333
        • van der Kolk D.M.
        • de Bock G.H.
        • Leegte B.K.
        • et al.
        Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
        Breast Cancer Res Treat. 2010; 124: 643-651
        • Mavaddat N.
        • Peock S.
        • Frost D.
        • et al.
        Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
        J Natl Cancer Inst. 2013; 29
        • van Roosmalen M.S.
        • Stalmeier P.F.
        • Verhoef L.C.
        • et al.
        Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers.
        J Clin Oncol. 2004; 22: 3293-3301
        • Spear S.L.
        • Carter M.E.
        • Schwarz K.
        Prophylactic mastectomy: indications, options, and reconstructive alternatives.
        Plast Reconstr Surg. 2005; 115: 891-909
        • Rebbeck T.R.
        • Friebel T.
        • Lynch H.T.
        • et al.
        Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
        J Clin Oncol. 2004; 22: 1055-1062
        • Gopie J.P.
        • Mureau M.A.
        • Seynaeve C.
        • et al.
        Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer.
        Fam Cancer. 2012;
        • Howard A.F.
        • Balneaves L.G.
        • Bottorff J.L.
        Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review.
        J Genet Couns. 2009; 18: 578-597
        • De Bock G.H.
        • Hesselink J.W.
        • Roorda C.
        • et al.
        Model of care for women at increased risk of breast and ovarian cancer.
        Maturitas. 2012; 71: 3-5
        • Unic I.
        • Verhoef L.C.
        • Stalmeier P.F.
        • van Daal W.A.
        Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women's treatment choices and medical and decision-analytic recommendations.
        Med Decis Making. 2000; 20: 251-262
        • Lodder L.N.
        • Frets P.G.
        • Trijsburg R.W.
        • et al.
        One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
        Breast Cancer Res Treat. 2002; 73: 97-112
        • van Dijk S.
        • van Roosmalen M.S.
        • Otten W.
        • Stalmeier P.F.
        Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.
        J Clin Oncol. 2008; 26: 2358-2363
        • Ray J.A.
        • Loescher L.J.
        • Brewer M.
        Risk-reduction surgery decisions in high-risk women seen for genetic counseling.
        J Genet Couns. 2005; 14: 473-484
        • van Dijk S.
        • Otten W.
        • Zoeteweij M.W.
        • et al.
        Genetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessment.
        Br J Cancer. 2003; 88: 1675-1681
        • Metcalfe K.A.
        • Foulkes W.D.
        • Kim-Sing C.
        • et al.
        Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
        Clin Genet. 2008; 73: 474-479
        • King T.A.
        • Sakr R.
        • Patil S.
        • et al.
        Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.
        J Clin Oncol. 2011; 29: 2158-2164
        • Yi M.
        • Hunt K.K.
        • Arun B.K.
        • et al.
        Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.
        Cancer Prev Res (Phila). 2010; 3: 1026-1034
        • Scheuer L.
        • Kauff N.
        • Robson M.
        • et al.
        Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
        J Clin Oncol. 2002; 20: 1260-1268
        • Beattie M.S.
        • Crawford B.
        • Lin F.
        • Vittinghoff E.
        • Ziegler J.
        Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
        Genet Test Mol Biomarkers. 2009; 13: 51-56
        • Metcalfe K.A.
        • Lubinski J.
        • Ghadirian P.
        • et al.
        Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
        J Clin Oncol. 2008; 26: 1093-1097
        • Schrag D.
        • Kuntz K.M.
        • Garber J.E.
        • Weeks J.C.
        Decision analysis – effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
        N Engl J Med. 1997; 336: 1465-1471
        • van Dooren S.
        • Seynaeve C.
        • Rijnsburger A.J.
        • et al.
        The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for hereditary breast cancer.
        Breast Cancer Res Treat. 2005; 89: 75-80